home
portfolio
team
careers
contact
investor portal
home
portfolio
team
careers
contact
investor portal
Nextech Invest
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742
Post navigation
Previous Post
Previous
Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results
Next Post
Next
PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights